Research advances of platelet-rich plasma in the treatment of interstitial cystitis/bladder pain syndrome
10.3969/j.issn.1009-8291.2025.12.014
- VernacularTitle:富血小板血浆在间质性膀胱炎/膀胱疼痛综合征治疗中的研究进展
- Author:
Qingwei ZHANG
1
;
Yuanqi GUO
1
;
Peng ZHOU
2
;
Jingde WU
1
;
Jianlin XIE
1
;
Shenglong LI
3
;
Xiande HUANG
2
Author Information
1. The First Clinical Medical College of Gansu University of Chinese Medicine, Lanzhou 730000
2. Department of Urology, Gansu Provincial People's Hospital, Lanzhou 730000
3. School of Integrative Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, China
- Publication Type:Journal Article
- Keywords:
interstitial cystitis;
bladder pain syndrome;
platelet-rich plasma
- From:
Journal of Modern Urology
2025;30(12):1096-1102
- CountryChina
- Language:Chinese
-
Abstract:
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a refractory condition characterized by chronic inflammation of the bladder wall, disruption of the urothelial barrier, and neural sensitization. Current therapies, such as oral pentosan polysulfate sodium (PPS) or intravesical hyaluronic acid instillations, offer limited efficacy due to transient effects and an inability to reverse tissue fibrosis. Platelet-rich plasma (PRP), a regenerative medicine approach, has demonstrated significant therapeutic potential in urological disorders through the synergistic actions of its multiple growth factors. This review summarizes the latest advances in PRP therapy for IC/BPS, revealing that the underlying mechanisms primarily involve the release of diverse growth factors, suppression of inflammatory responses, restoration of the urothelial barrier, and modulation of nerve axonal regeneration. Clinically, PRP therapy significantly alleviates symptoms including pelvic/bladder pain, urinary frequency, nocturia episodes, and improves patients'quality of life. Furthermore, it offers advantages such as convenient administration, a favorable safety profile, and strong feasibility, presenting new therapeutic methods and options for the clinical treatment of IC/BPS.
